Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
- Status
- COMPLETED
- Phase
- PHASE1
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
- Status
- WITHDRAWN
- Phase
- PHASE1
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
The Drug Rediscovery Protocol (DRUP Trial)
- Status
- RECRUITING
- Phase
- PHASE2